Bavituximab Completed Phase 2 Trials for Breast Cancer Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00669591A Safety and Efficacy Study of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer